Ultrasound contrast agent developer Acusphere of Cambridge, MA, has begun phase II clinical trials of its third-generation agent for assessing myocardial perfusion in patients with coronary artery disease (CAD). The company’s phase II trial will
Ultrasound contrast agent developer Acusphere of Cambridge, MA, has begun phase II clinical trials of its third-generation agent for assessing myocardial perfusion in patients with coronary artery disease (CAD). The companys phase II trial will evaluate the best imaging conditions for the assessment of myocardial perfusion in patients with CAD after a single dose of AI-700. Acusphere hopes that AI-700 could offer clinicians a low-cost alternative to nuclear medicine perfusion scans.
First-generation agents last for about a minute when illuminating the endocardium within the ventricles of the heart. Second-generation technology provides four or five minutes of continuous imaging in this application. Ultrasound contrast developers such as Acusphere hope that third-generation agents will extend imaging time to 20 to 30 minutes, or about the time of a cardiac ultrasound examination (SCAN 6/23/99).
Studies have suggested that AI-700 could be used in a continuous mode, allowing clinicians to overcome some of the shortcomings of other agents, which have short persistence times because their contrast-enhancing microbubbles break up under ultrasound beams, according to the company (SCAN 4/14/99). Acusphere believes that the AI-700 microbubbles may have longer persistence times because they are made from synthetic polymers.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.